Currently in the contract manufacturing industry, demand outruns...
pharmatechoutlook

Pharma Tech Outlook: Pharma Tech Magazine

Currently in the contract manufacturing industry, demand outruns supply.

Pharma Tech Outlook | Monday, December 13, 2021

According to a new CRB market assessment report that is based on survey responses from more than 500 pharma representatives on important concerns confronting their companies, organization who rely primarily on CMOs or CDMOs, on the other hand, confront a big challenge that demand outruns supply, and many contract manufacturers have unreasonably long lead times.

FREMONT, CA: As capital project delivery returns to pre-pandemic levels in the coming months and years, smaller biopharma enterprises are going outside their own resources for strategic manufacturing and research support, according to a new CRB market assessment. This report is based on survey responses from more than 500 pharma representatives on important concerns confronting their companies. According to the CRB team, this was a job that smoothed their reputation to a shine and demonstrated that extraordinary speed and scalability are attainable through strategic collaborations.

Companies who rely primarily on CMOs or CDMOs, on the other hand, confront a big challenge that demand outruns supply, and many contract manufacturers have unreasonably long lead times. Large pharmaceutical corporations appear to have factored utilizing a hybrid in-house/CDMO strategy or only work in-house this into their manufacturing strategy. According to the data compiled in the CRB report, only 18 percent rely only on CDMOs. They suspected that preserving intellectual property (IP) may also play a role, because larger organizations stand to lose a lot if their IP is leaked and have more resources to secure that IP by keeping it in-house. For new businesses, there is approximately an equal split between in-house and CDMO manufacture, with capital cost being the most important driver. Anyway, large corporations are better positioned than start-ups to reduce their reliance on outsourced production, according to experts in the life science business. For instance, they are more likely to have the ability and capital to vertically integrate specific operations, such as the important fill-finish stage. As they scale toward commercialization, most start-ups do not have this option.

Weekly Brief

Read Also